Hormone Therapy for Stage 2 Breast Cancer: 73 Real Stories

Stage IIA male breast cancer: chemotherapy, mastectomy, endocrine therapy, and benign adrenal nodule

Patient Info: Anonymized, Male, 50s | Stage II

Biomarkers: ER-positive; PR-positive; HER2-negative

Final breast cancer pathology was T1N1M0 / AJCC Stage IIA ER-positive, PR-positive, HER2-negative invasive ductal carcinoma; the suspicious adrenal lesion was removed in June 2025 and proved to be a benign adrenal adenoma.

PubMed CentralRead more →

Stage IIB HER2-positive apocrine breast carcinoma treated with chemotherapy, trastuzumab, radiation, and tamoxifen

Patient Info: Anonymized, Female, Under 40 | Stage II

Biomarkers: ER 80%; PR 5%; HER2-positive by HercepTest and FISH; Ki-67 15%; AR testing not performed

At 7 months of follow-up, the patient remained in remission, with no locoregional recurrence or distant metastasis reported.

PubMed CentralRead more →

Stage II HR-Positive Breast Cancer: Kelsey's Patient Story

Patient Info: Kelsey, Female, Under 40 | Stage II

Biomarkers: ER-positive

As of May 2025, Kelsey had completed chemotherapy, double mastectomy with reconstruction, and 16 radiation sessions, and was continuing tamoxifen with Verzenio planned for 2 years plus Lupron ovarian-suppression shots.

The Patient StoryRead more →

Stage II HR-Positive Invasive Ductal Carcinoma: LaShae's Patient Story

Patient Info: LaShae, Female, Under 40 | Stage II

Biomarkers: ER-positive; comprehensive genetic panel negative

As of May 2025, LaShae had completed mastectomy for Stage IIB ER-positive breast cancer with 2 positive lymph nodes and was undergoing chemotherapy, with radiation and 5-10 years of hormone therapy planned.

The Patient StoryRead more →

Stage IIA ER-positive breast cancer with axillary tuberculosis: no metabolically active disease after treatment

Patient Info: Anonymized, Female, 60s | Stage II

Biomarkers: ER 78% positive; PR-negative; HER2/neu-negative; Ki-67 21%; Luminal A subtype

As of April 2025, follow-up PET-CT showed no metabolically active disease after mastectomy, adjuvant anthracycline-based chemotherapy, letrozole, and 6 months of anti-tuberculosis therapy.

PubMed CentralRead more →

Right Stage IIB ER/PR-positive breast cancer with left epithelioid MPNST: no recurrence after surgery

Patient Info: Anonymized, Female, 70+ | Stage II

Biomarkers: Right breast cancer was ER/PR-positive, HER2-negative/1+

As of March 2025, 3 years after bilateral mastectomy, there was no recurrence of the right breast cancer or the left epithelioid malignant peripheral nerve sheath tumor; she remained on anastrozole for the right breast cancer.

PubMed CentralRead more →

Stage II HR-Positive Invasive Lobular Carcinoma: Karen's Survivor Story

Patient Info: Karen, Female, 40s | Stage II

Biomarkers: ER-positive; PR-positive; HER2-negative; grade 2; inherited genetic testing negative

Karen completed double mastectomy, 3 months of chemotherapy and reconstruction. She was doing well on ongoing endocrine and targeted therapy and walking 3–5 miles daily.

Lobular Breast Cancer AllianceRead more →

ER-positive breast cancer: mastectomy after hormone therapy

Patient Info: Anonymized, Female, 50s | Stage II

Biomarkers: Breast cancer was ER+ and HER2-low/negative. PR changed from positive on biopsy to negative on final pathology; HNA-1 antibody found for neutropenia.

Stage IIA ER-positive invasive ductal breast cancer had no recurrence 3 years after endocrine therapy and total mastectomy with sentinel lymph node biopsy; autoimmune neutropenia was monitored rather than directly treated.

PubMed CentralRead more →

Finding A Lump To BREAST CANCER!

Patient Info: Kelsey Harrison, Female, Under 40 | Stage II

Biomarkers: ER-positive

As of July 2024, Kelsey had completed chemotherapy, double mastectomy with axillary lymph-node removal, and radiation, and was continuing tamoxifen plus Lupron ovarian suppression with additional planned systemic therapy.

The Patient StoryRead more →

Stage II Invasive Lobular Carcinoma: Lizzie's Survivor Story

Patient Info: Lizzie, Female | Stage II

Lizzie completed mastectomy, reconstruction-related surgery and 5 weeks of radiation. She remained on a planned 10-year course of an aromatase inhibitor and became active in breast cancer research advocacy.

Lobular Breast Cancer AllianceRead more →

Stage II HR-Positive Invasive Ductal Carcinoma: Allison's Patient Story

Patient Info: Allison Tierney, Female | Stage II

Biomarkers: ER-positive; PR-positive; HER2-positive; CHEK2 mutation; BRCA1/2 negative

As of March 2024, Allison had completed Taxol and Herceptin treatment, was on tamoxifen planned for 10 years, and had moved to 6-month oncology follow-up. No metastatic disease or recurrence was reported.

YouTube — The Patient StoryRead more →

HER2-positive Stage IIB breast cancer complicated by acute neuro-Behcet disease during neoadjuvant treatment

Patient Info: Anonymized, Female, 40s | Stage II

Biomarkers: ER-positive; PgR/PR-positive; HER2-positive by FISH amplification; Ki-67 index 50%

As of June 2024, there was no recurrence of breast cancer or neuro-Behcet disease 2 years after surgery and postoperative HER2-directed plus endocrine therapy.

PubMed CentralRead more →

Stage II Breast Cancer: Paula's Patient Story

Patient Info: Paula | Stage II

Paula was receiving chemotherapy and hormonal therapy for stage 2 breast cancer, with additional treatments included in the recommended plan.

Our Cancer StoriesRead more →

Stage II HR-Positive Invasive Lobular Carcinoma: Megan's Survivor Story

Patient Info: Megan Claire Chase, Female | Stage II

Biomarkers: ER-positive; PR-positive; HER2 not reported

As of July 2023, Megan-Claire was in survivorship after Stage II invasive lobular breast cancer, with clear early scans but significant long-term effects, surgical menopause, chronic pain, fatigue, chemo brain, and inability to tolerate recurrence-prevention medications.

The Patient StoryRead more →

Stage IIB Breast Cancer Treatment Followed by BRCA1 Testing

Patient Info: Anonymized, Female | Stage II

Biomarkers: BRCA1 pathogenic variant

She completed 10 years of endocrine therapy without evidence of breast-cancer recurrence.

PubMed CentralRead more →

HER2-positive breast cancer on hemodialysis: partial response to T-DM1 then no metabolically active disease

Patient Info: Anonymized, Female, 60s | Stage II

Biomarkers: Hormone receptor-positive; HER2/neu-positive; E-cadherin-positive; Ki-67 55-60%; luminal B type

As of March 2023, after 12 total cycles of T-DM1 and modified radical mastectomy, PET-CT showed no metabolically active disease, and she continued endocrine therapy and dialysis.

PubMed CentralRead more →

Stage II Breast Cancer: Renée's Patient Story

Patient Info: Renée, Female, Under 40 | Stage II

Biomarkers: Not genetically inherited; breast cancer linked by her team to prior doxorubicin exposure and total-body radiation

As of February 2023, Renée described stable health, working treatments, good bloodwork, and ongoing long-term hormone/anti-cancer therapy; she did not consider herself cancer-free and preferred survivor/thriver language.

The Patient StoryRead more →

Stage II Breast Cancer: Alicia's Patient Story

Patient Info: Alicia, Female, 50s | Stage II

As of 2023, Alicia had undergone Stage II breast cancer treatment with mastectomy, hormone therapy, and DIEP flap reconstruction, with no treatment side effects described and a focus on recovery and wellbeing.

Our Cancer StoriesRead more →

Stage II Breast Cancer: Maiv's Patient Story

Patient Info: Maiv | Stage II

Maiv had completed active treatment and remained on hormone therapy at the time of her story.

Our Cancer StoriesRead more →

Stage II Breast Cancer: Angelina's Patient Story

Patient Info: Angelina, Female, 50s | Stage II

As of 2023, Angelina was undergoing Stage II breast cancer treatment with DIEP mastectomy, chemotherapy, radiation therapy, and hormone therapy, and was focused on recuperation and future goals.

Our Cancer StoriesRead more →

Stage II Breast Cancer: Annie's Patient Story

Patient Info: Annie, Female, 40s | Stage II

As of 2023, Annie was still receiving care for Stage II breast cancer after completing chemotherapy and hormonal therapy, with lumpectomy, lymphadenectomy, radiation therapy, and immunotherapy still ahead in her plan.

Our Cancer StoriesRead more →

Stage II Breast Cancer: Margaret's Patient Story

Patient Info: Margaret | Stage II

Margaret chose mastectomy and hormone therapy and reported no treatment side effects while remaining optimistic about recovery.

Our Cancer StoriesRead more →

Stage II Breast Cancer: Rose's Patient Story

Patient Info: Rose | Stage II

Rose remains on radiotherapy, hormone therapy and targeted therapy while continuing to live with concerns about recurrence and metastasis.

Our Cancer StoriesRead more →

Stage II Breast Cancer: Lan's Patient Story

Patient Info: Lan | Stage II

Lan had completed surgery, chemotherapy, and radiation and remained on hormone therapy, with ongoing concern about treatment effects but growing optimism.

Our Cancer StoriesRead more →